Testosterone is a crucial hormone for men and plays an important role throughout the male lifespan. Most of a male's testosterone is produced through the testicles. Also called the male sex hormone, testosterone starts playing its part during puberty.
When a male goes through puberty, testosterone helps males develop:
As boys turn to men and men grow older, testosterone levels deplete naturally. Sometimes, events like injuries and chronic health conditions like diabetes can lower testosterone levels. Unfortunately, when a man loses too much T, it results in hypogonadism. When this happens, the testosterone must be replaced, or the male will suffer from symptoms like muscle loss, low libido, and even depression.
TRT is exactly what it sounds like: a treatment option for men that replaces testosterone so that your body regulates hormones properly and restores balance to your life. Also called androgen replacement therapy, TRT alleviates the symptoms that men experience with low T.
Originally lab-synthesized in 1935, testosterone has grown in popularity since it was produced. Today, TRT and other testosterone treatments are among the most popular prescriptions in the U.S.
Without getting too deep into the science, TRT works by giving your body the essential testosterone it needs to function correctly. As the primary androgen for both males and females, testosterone impacts many of the body's natural processes â especially those needed for overall health. For example, men with low T are more prone to serious problems like cardiovascular disease and even type-2 diabetes.
When your body quits making enough testosterone, it causes your health to suffer until a solution is presented. That's where TRT and anti-aging medicine for men can help. TRT helps balance your hormones and replenish your depleted testosterone. With time, your body will begin to heal, and many symptoms like low libido and irritability begin to diminish.
For men, aging is the biggest contributor to lower testosterone levels, though there are other causes like obesity, drug abuse, testicular injuries, and certain prescribed medications. Sometimes, long-term health conditions like AIDS, cirrhosis of the liver, and kidney disease can lower testosterone levels.
When a man's testosterone levels drop significantly, it alters his body's ratio of estrogen and testosterone. Lower testosterone levels cause more abdominal fat, which in turn results in increased aromatase, which converts even more testosterone into estrogen.
If you're concerned that you might have low T, you're not alone. Millions of men in the U.S. feel the same way. The best way to find out if your testosterone is low is to get your levels tested.
For sustainable testosterone replacement therapy benefits, you must consult with hormone doctors and experts like those you can find at Global Life Rejuvenation. That way, you can find the root cause of your hormone problems, and our team can craft a personalized HRT plan tailored to your needs.
One of the most common reasons that men choose TRT is because they have lost that "spark" with their partner. It's not easy for a man to hear that they're not performing like they used to. Intimacy is a powerful part of any relationship. When a once-healthy sex life dwindles, it can cause serious relationship issues.
The good news is that low libido doesn't have to be a permanent problem. TRT and anti-aging medicines help revert hormone levels back into their normal range. When this happens, many men have a more enjoyable life full of intimacy and sex drive.
Weak erections â it's an uncomfortable subject for many men in the U.S. to talk about. It's even worse to experience first-hand. You're in the midst of an intimate moment, and you can't do your part. Despite being perfectly normal, many men put blame and shame upon themselves when they can't achieve an erection. And while the inability to perform sexually can be caused by poor diet, obesity, and chronic health conditions, low testosterone is often a contributing factor.
Fortunately, weak erections are a treatable condition. The best way to regain your confidence and ability in bed is to speak with your doctor. Once any underlying conditions are discovered, options like TRT may be the best course of treatment.
Do you find it harder and harder to work out and lift weights in the gym? Are you having problems lifting heavy items that you once had no problem lifting?
Recent studies show that when men are inactive, they lose .5% of muscle strength every year, from ages 25 to 60. After 60, muscle loss doubles every decade. While some muscle loss is common as men age, a significant portion can be tied to low testosterone levels. When a man's T levels drop, so does his muscle mass.
Testosterone is a much-needed component used in gaining and retaining muscle mass. That's why many doctors prescribe TRT Woodcliff Lake, NJ, for men having problems with strength. One recent study found that men who increased their testosterone levels using TRT gained as much as 2.5 pounds of muscle mass.
Whether your gym performance is lacking, or you can't lift heavy items like you used to, don't blame it all on age. You could be suffering from hypogonadism.
If you're like millions of other men in their late 20s and 30s, dealing with hair loss is a reality you don't want to face. Closely related to testosterone decline and hormone imbalances, hair loss is distressing for many men. This common symptom is often related to a derivative of testosterone called DHT. Excess amounts of DHT cause hair follicles to halt their production, causing follicles to die.
Because hair located at the front and crown is more sensitive to DHT, it grows slower than other follicles and eventually stops growing permanently. Thankfully, TRT and anti-aging treatments for men in Woodcliff Lake, NJ, is now available to address hair loss for good.
While it's true that you can't change your genes, you can change the effects of low testosterone on your body. Whether you're suffering from thinning hair or hair loss across your entire head, TRT and other hormone therapies can stop hair loss and even reverse the process.
Also called "man boobs," gynecomastia is essentially the enlargement of male breast tissue. This increase in fatty tissue is often caused by hormonal imbalances and an increase in estrogen. For men, estrogen levels are elevated during andropause. Also called male menopause, andropause usually happens because of a lack of testosterone.
If you're a man between the ages of 40 and 55, and you're embarrassed by having large breasts, don't lose hope. TRT is a safe, effective way to eliminate the underlying cause of gynecomastia without invasive surgery. With a custom HRT and fitness program, you can bring your testosterone and estrogen levels back to normal before you know it.
Decreased energy was once considered a normal part of aging. Today, many doctors know better. Advances in technology and our understanding of testosterone show that low T and lack of energy often go hand-in-hand.
If you're struggling to enjoy activities like playing with your kids or hiking in a park due to lack of energy, it could be a sign of low T. Of course, getting tired is perfectly normal for any man. But if you're suffering from continual fatigue, a lack of enjoyment, or a decrease in energy, it might be time to speak with a doctor.
Whether you're having a tough time getting through your day or can't finish activities you used to love, TRT could help.
A study from 2011 showed that men who lose a week's worth of sleep can experience lowered testosterone levels â as much as 15%, according to experts. Additional research into the topic found almost 15% of workers only get five hours of sleep (or less) per night. These findings suggest that sleep loss negatively impacts T levels and wellbeing.
The bottom line is that men who have trouble sleeping often suffer from lower testosterone levels as a result. If you find yourself exhausted at the end of the day but toss and turn all night long, you might have low T.
TRT and anti-aging medicines can restore your T levels back to normal, which can help you sleep better with proper diet and exercise.
You're feeling down about everything, and there's no solid explanation for why you're in such a crummy mood. Your daily life is great and full of success, but you can't help but feel unexcited and unmotivated. If you're experiencing symptoms like these, you may be depressed â and it may stem from low testosterone.
A research study from Munich found that men with depression also commonly had low testosterone levels. This same study also found that depressed men had cortisol levels that were 67% higher than other men. Because higher cortisol levels lead to lower levels of testosterone, the chances of severe depression increase.
Depression is a very real disorder and should always be diagnosed and treated by your doctor. One treatment option gaining in popularity is TRT for depression. Studies show that when TRT is used to restore hormone levels, men enjoy a lighter, more improved mood. That's great news for men who are depressed and have not had success with other treatments like anti-depression medicines, which alter the brain's chemistry.
Ask anyone over the age of 50 how their memory is, and they'll tell you it wasn't what it used to be. Memory loss and lack of concentration occur naturally as we age â these aren't always signs of dementia or Alzheimer's.
However, what many men consider a symptom of age may be caused by low testosterone. A 2006 study found that males with low T levels performed poorly on cognitive skill tests. These results suggest that low testosterone may play a part in reducing cognitive ability. If you're having trouble staying on task or remembering what your schedule is for the day, it might not be due to your age. It might be because your testosterone levels are too low. If you're having trouble concentrating or remembering daily tasks, it could be time to talk to your doctor.
Why? The aforementioned study found that participating men experienced improved cognitive skills when using TRT.
Even though today's society is more inclusive of large people, few adults enjoy gaining weight as they age. Despite their best efforts, many men just can't shed the extra pounds around their midsections, increasing their risk of heart disease and cancer.
Often, male weight gain is caused by hormone imbalances that slow the metabolism and cause weight to pile on. This phase of life is called andropause and happens when there is a lack of testosterone in the body. Couple that with high cortisol levels, and you've got a recipe for flabby guts and double chins.
Fortunately, TRT treatments and physician-led weight loss programs can correct hormone imbalances and lead to healthy weight loss for men.
Sermorelin is a synthetic hormone peptide, like GHRH, which triggers the release of growth hormones. When used under the care of a qualified physician, Sermorelin can help you lose weight, increase your energy levels, and help you feel much younger.
Human growth hormone (HGH) therapy has been used for years to treat hormone deficiencies. Unlike HGH, which directly replaces declining human growth hormone levels, Sermorelin addresses the underlying cause of decreased HGH, stimulating the pituitary gland naturally. This approach keeps the mechanisms of growth hormone production active.
Benefits of Sermorelin include:
Ipamorelin helps to release growth hormones in a person's body by mimicking a peptide called ghrelin. Ghrelin is one of three hormones which work together to regulate the growth hormone levels released by the pituitary gland. Because Ipamorelin stimulates the body to produce growth hormone, your body won't stop its natural growth hormone production, which occurs with synthetic HGH.
Ipamorelin causes growth hormone secretion that resembles natural release patterns rather than being constantly elevated from HGH. Because ipamorelin stimulates the natural production of growth hormone, our patients can use this treatment long-term with fewer health risks.
One of the biggest benefits of Ipamorelin is that it is suitable for both men and women. It provides significant short and long-term benefits in age management therapies, boosting patients' overall health, wellbeing, and outlook on life. When growth hormone is produced by the pituitary gland using Ipamorelin, clients report amazing benefits.
Some of those benefits include:
Whether you are considering our TRT services, HRT for women, or our growth hormone peptide services, we are here to help. The first step to turning back the hand of time starts by contacting Global Life Rejuvenation.
Our friendly, knowledgeable TRT and HRT experts can help answer your questions and walk you through our procedures. From there, we'll figure out which treatments are right for you. Before you know it, you'll be well on your way to looking and feeling better than you have in years!973-587-8638
Real Estate The Garden State’s commercial real estate community recognized the achievements of leading professionals and firms and the state’s most impactful transactions of 2022 as NAIOP New Jersey hosted its 35th Annual Commercial Real Estate Awards Gala recently at the Palace at Somerset Park.In his opening remarks, NAIOP NJ President Constantino T. “Gus” Milano, president and COO of Hartz Mountain Industries, said, “Our honorees truly represent the best of real estate and economic development. ...
The Garden State’s commercial real estate community recognized the achievements of leading professionals and firms and the state’s most impactful transactions of 2022 as NAIOP New Jersey hosted its 35th Annual Commercial Real Estate Awards Gala recently at the Palace at Somerset Park.
In his opening remarks, NAIOP NJ President Constantino T. “Gus” Milano, president and COO of Hartz Mountain Industries, said, “Our honorees truly represent the best of real estate and economic development. They’re inspired by a commitment to excellence in transforming New Jersey communities, and all of them will have a lasting, positive impact on our state and our industry.”
The Charles Klatskin Lifetime Achievement Award was presented to Gene Preston, who recently retired from Dermody Properties. Preston developed and acquired nearly 28 million square feet of industrial and logistics space representing approximately $2 billion of invested capital during his career. An active member of NAIOP for 33 years, he served as president of the New Jersey Chapter in 2019 and 2020.
David Gockel, president/CEO of Langan, and Onyx Equities, whose founders and managing principals are John Saraceno and Jonathan Schultz, accepted the Impact Award in recognition of their influence on the industrial and office development communities. Anthony Coscia, partner at Windels Marx Lane & Mittendorf LLP, was honored with the Industry Service Award in recognition of his considerable contributions in support of the industry’s goals.
The Caren S. Franzini Public Partner Award, which recognizes champions of economic development that inspire and transform communities, was presented to City of Linden Mayor Derek Armstead.
In addition to celebrating the achievements of leading commercial real estate professionals and firms, NAIOP NJ recognized the year’s most impactful real estate transactions. Deal of the Year winners in three categories – Industrial, Office and Mixed-Use – were chosen by a panel of judges based on impact on the community and marketplace; degree of complexity and/or uniqueness; innovative strategies; and creative problem solving.
Office Deal of the Year: Party City Headquarters Operations Lease, Woodcliff Lake. As the first-ever New Jersey Economic Development Authority Emerge Program recipient, Party City Holdings Inc. secured a 7-year, $9.996 million tax credit for its 208,911-square-foot Class A headquarters lease at 100 Tice Blvd. Involved in the deal: Party City, Cushman & Wakefield, Savills Studley, CBRE, Inc. and Gensler.
Industrial Deal of the Year: Target at Logan North, Logan Township. The team of Greek Development, Advance Realty Investors and CBRE successfully leased a 1.7-million-square-foot omnichannel flow center to Target Corp. The asset traded for a record-breaking $265 million when Torchlight Investors of New York bought the building in September 2021.
Mixed-Use Deal of the Year: HalRay Newark Portfolio, Newark. The HalRay Newark Portfolio is a three-building portfolio totaling approximately 800,000 square feet of office/retail space with a 901-space parking deck. The sponsors have planned approximately $40 million of capital improvements with the goal of driving further activity along the Halsey Corridor and throughout the city. Involved in the deal: Hanini Group, Shift Capital, Colnvestment Partners, Murphy Schiller & Wilkes LLP and JLL Capital Markets.
A special Transformation Award went to RCINJ Jack & Sheryl Morris Cancer Center, a partnership among New Brunswick Development Corporation (Devco), Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, Robert Wood Johnson University Hospital, Rutgers Biomedical & Health Sciences and Middlesex County that will bring New Brunswick the state’s first freestanding cancer hospital.
To access more business news, visit NJB News Now.
Margaret Qualley and Jack Antonoff answered headline speculation with photographic evidence.The couple, who were rumored to be engaged, confirmed their impending union with a series of pictures that prominently showcase Qualley’s ring as the actor embraces the musician.“Oh I love him!” Qualley said in her caption for the Instagram post Tues...
The couple, who were rumored to be engaged, confirmed their impending union with a series of pictures that prominently showcase Qualley’s ring as the actor embraces the musician.
“Oh I love him!” Qualley said in her caption for the Instagram post Tuesday, tagging her husband-to-be.
Antonoff, who wears a Whitney Houston shirt in the engagement selfies, grew up in New Milford and Woodcliff Lake.
Qualley, 27, and Antonoff, 38, were first linked last summer.
Antonoff, who performs as Bleachers, is a Grammy-winning producer and songwriter who has worked with artists like Taylor Swift, St. Vincent, Florence and the Machine and Lana Del Rey, winning the 2022 Grammy for producer of the year (non-classical). He was formerly a member of the band Fun.
Qualley also appeared in HBO’s “The Leftovers” and the films “Stars At Noon,” directed by Claire Denis, which just premiered at the Cannes Film Festival (where it won the Grand Prix) and Quentin Tarantino’s “Once Upon a Time... In Hollywood” (2019). She received her first Emmy nomination in 2019 for playing Ann Reinking in the FX miniseries “Fosse/Verdon” and was nominated for a Golden Globe for her lead role in “Maid.”
Antonoff was previously in a long-term relationship with Lena Dunham, the writer, director and actor who created the HBO series “Girls.” Dunham married musician Luis Felber in 2021.
Qualley previously dated Pete Davidson and Shia LeBeouf.
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- PowerFleet, Inc. (Nasdaq: PWFL), a global leader of SaaS-based data insight solutions that manage enterprise assets, enabling unification of their business operations, will virtually host its inaugural Investor Day on Tuesday, June 14, 2022 from 11:30 a.m. to 2:30 p.m. Eastern t...
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- PowerFleet, Inc. (Nasdaq: PWFL), a global leader of SaaS-based data insight solutions that manage enterprise assets, enabling unification of their business operations, will virtually host its inaugural Investor Day on Tuesday, June 14, 2022 from 11:30 a.m. to 2:30 p.m. Eastern time.
PowerFleet CEO Steve Towe will be joined by CTO Jim Zeitunian, CRO Patrick Maley and other senior executives to discuss the company’s enhanced vision, growth drivers, go-to-market strategy, software and AI roadmap, and target financial model. The event will include interactive Q&A and product demonstrations that highlight how global companies can unify their IoT data, manage macro-economic challenges such as rising fuel prices as well as leverage data science to drive more profitable business decisions.
About PowerFleetPowerFleet® Inc. (NASDAQ: PWFL; TASE: PWFL) is a global leader of subscription-based wireless solutions that manage enterprise assets for seamless business operations. PowerFleet’s patented technologies are the proven solution for organizations that must monitor and analyze their assets to improve safety, increase efficiency, reduce costs, and drive profitability. Our offerings are sold under the global brands PowerFleet, Pointer, and Cellocator. PowerFleet’s global headquarters are in Woodcliff Lake, New Jersey, with additional offices around the globe. For more information, please visit www.powerfleet.com, the content of which does not form a part of this press release.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements with respect to PowerFleet’s beliefs, plans, goals, objectives, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond PowerFleet’s control, and which may cause its actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. For example, forward-looking statements include statements regarding prospects for additional customers; potential contract values; market forecasts; projections of earnings, revenues, synergies, accretion, or other financial information; emerging new products; and plans, strategies, and objectives of management for future operations, including growing revenue, controlling operating costs, increasing production volumes, and expanding business with core customers. The risks and uncertainties referred to above include, but are not limited to, future economic and business conditions, the ability to recognize the anticipated benefits of the acquisition of Pointer, which may be affected by, among other things, the loss of key customers or reduction in the purchase of products by any such customers, the failure of the market for PowerFleet’s products to continue to develop, the possibility that PowerFleet may not be able to integrate successfully the business, operations and employees of I.D. Systems and Pointer, the inability to protect PowerFleet’s intellectual property, the inability to manage growth, the effects of competition from a variety of local, regional, national and other providers of wireless solutions, and other risks detailed from time to time in PowerFleet’s filings with the Securities and Exchange Commission, including PowerFleet’s annual report on Form 10-K for the year ended December 31, 2021. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PowerFleet. Unless otherwise required by applicable law, PowerFleet assumes no obligation to update the information contained in this press release, and expressly disclaims any obligation to do so, whether a result of new information, future events, or otherwise.
PowerFleet Media ContactCalen McGee[email protected](908) 461-0266
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter ---- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting ---- Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for prop...
-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter --
-- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. Food and Drug Administration (“FDA”) provided during AOP Health’s Type C meeting --
-- Enrollment of study of pediatric patients with supraventricular tachycardia is underway in Europe and is designed to serve as the basis for proposed pediatric study plans for a future FDA submission --
-- If landiolol is approved, Eagle expects five years of new chemical entity exclusivity --
WOODCLIFF LAKE, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group (“AOP Health”), with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for landiolol, a short-acting, intravenous (“IV”), cardio-selective beta-1 adrenergic blocker. The submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.
“The submission of the landiolol NDA is a significant step forward for our company, as we look to bring this important therapeutic candidate to the U.S. market and to expand our footprint in the acute care setting. We believe that landiolol has the potential to become a cornerstone therapy in the management of tachycardia in critically ill patients. Landiolol has differentiated clinical characteristics and an established safety profile, and we look forward to working with FDA during the course of the review process,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
“We are successfully diversifying our revenue stream, anticipated to grow from three commercial products just last year to eight upon the closing of the anticipated Acacia Pharma transaction, and nine with landiolol, if approved. We look forward to the potential of adding another strong product to our portfolio and to leveraging our highly capable hospital-based sales force,” concluded Tarriff.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin injection, PEMFEXY™, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at .
Lisa M. WilsonIn-Site Communications, Inc. T: 212-452-2793 E:
Party City Holdings Inc. is relocating its global headquarters to a Woodcliff Lake office building beginning in 2022, according to a Thursday announcement from Signature Acquisitions.The largest retailer of party goods in North America signed a full-building lease at 100 Tice Blvd., a 208,911-square-foot Class A office building.Ben Brenner of ...
The largest retailer of party goods in North America signed a full-building lease at 100 Tice Blvd., a 208,911-square-foot Class A office building.
Ben Brenner of Cushman & Wakefield and Harlan Hollander of Savills represented Party City, and Joe Sarno Sr., Jon Meisel and Jeff Babikian of CBRE represented Signature Acquisitions in the transaction.
Originally founded in East Hanover, the company’s headquarters operations were spread across two offices, in Rockaway and Elmsford, New York. In September, the company said it was seeking to consolidate its headquarters operations, and Woodcliff Lake and the surrounding Upper Parkway submarket’s strong underlying fundamentals made it stand out among competing areas in the region.
The Fortune 100 company was the first to win an award under the Emerge program, the new job creation incentive touted by Gov. Phil Murphy and created under the New Jersey Economic Recovery Act of 2020. It will be bringing its headquarters — and 357 new jobs — to Bergen County, in accordance with a seven-year award for just under $10 million ($9,996,000) that was approved by the board of the New Jersey Economic Development Authority.
Conveniently located less than one mile from the Garden State Parkway and five miles from Interstates 87 and 287 in the borough of Woodcliff Lake, the asset is a three-story building that was acquired by Signature Acquisitions in 2019. Party City recognized that the building’s superior connectivity to regional transportation networks, its strong local demographics and its adaptability made it an ideal future headquarters location.
The building’s proximity to the New Jersey-New York border provides the company’s current employees with added convenience and accessibility while expanding its reach to attract additional top talent. Party City will take advantage of the EDA’s Emerge program award to fund major capital improvements at the building that will create a collaborative workplace geared to the needs of the growing company and its employee base.
“Our focus on acquiring best-in-class suburban office spaces and maintaining them to the highest standards has consistently created one-of-a-kind corporate destinations geared towards the needs of companies today,” said Rich Travaglini, senior vice president/director of leasing for Signature Acquisitions. “Party City’s return to New Jersey exemplifies our portfolio’s continued deep appeal to a wide range of companies hoping to tap into all that makes the tri-state area unique.
“We welcome Party City back to Garden State and we look forward to working with them to create a dynamic workplace that will foster the collaboration and creativity necessary for continued growth.”